Animal study · mice

AOD-9604 lowered body weight and body fat in obese mice over 14 days

Checked against the paper Animal studyPublished by PepVault

The takeaway

This early mouse study found weight and fat loss with AOD-9604 in obese mice, and the authors concluded its fat-breakdown effect does not act directly through beta-3 receptors. It is not a human result.

Kind
Animal study
Studied in
Mice
Published
2001
Journal
Endocrinology

What they tested

The team tested whether long-term AOD-9604 and human growth hormone reduce body weight and fat in obese mice, and whether that effect depends on beta-3 adrenergic receptors, the main fat-breakdown receptor on fat cells.

How the study was done

A study in mice. Obese mice got AOD-9604 or human growth hormone by injection into the abdominal cavity for 14 days, and long-term treatment was also tested in knock-out mice lacking beta-3 receptors against normal control mice. A separate short-term (acute) experiment gave AOD-9604 to the knock-out mice.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking AOD-9604? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In obese mice, both AOD-9604 and human growth hormone lowered body weight and body fat over 14 days. Both raised levels of beta-3 receptor RNA, which were low in obese mice, to about the levels seen in lean mice. In knock-out mice without beta-3 receptors, long-term treatment did not change body weight or raise lipolysis (fat breakdown) the way it did in normal mice. In the short-term experiment, AOD-9604 still raised energy expenditure and fat oxidation (fat burning) in the knock-out mice.

What it doesn’t show

This was work in mice, not people, and the treatment period was only 14 days. It does not show whether the same effects occur in humans.

The paper

Heffernan et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001.

The compound

More studies on AOD-9604

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking AOD-9604? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo